In This Section

Recent Press Releases

November 29, 2016

-- Transaction creates strong, diversified rare-disease focused portfolio

-- Novelion Therapeutics completes concurrent financing of approximately $22 million

-- Company to host conference call today at 4:30 p.m. ET

November 17, 2016

CAMBRIDGE, Mass., Nov. 17, 2016  -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Japan's Ministry of Health, Labor & Welfare (MHLW) has approved pricing of JUXTAPID in Japan. The pricing authorization follows Japanese regulatory approval of Juxtapid for the treatment of homozygous familial hypercholesterolemia (HoFH) on September 28, 2016.

November 7, 2016

VANCOUVER, British Columbia, Nov. 07, 2016 -- QLT Inc. (NASDAQ:QLTI) (TSX:QLT) (“QLT”) announced today certain matters relating to the previously announced transactions (the “Transactions”) contemplated in connection with an agreement and plan of merger dated as of June 14, 2016 (the “Merger Agreement”) involving QLT and Aegerion Pharmaceuticals, Inc. (“Aegerion”).

Shareholder Approval